









Cellular signalling pathways mediating the pathogenesis of chronic inflammatory respiratory diseases: An update
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Respiratory disorders, especially non-communicable, chronic inflammatory diseases, are amongst the leading causes of mortality and morbidity worldwide. Respiratory diseases involve multiple pulmonary components, including airways and lungs that lead to their abnormal physiological functioning. Several signaling pathways have been reported to play an important role in the pathophysiology of respiratory diseases. These pathways, in addition, become the compounding factors contributing towards the clinical outcomes in respiratory diseases.  A range of signaling components such as Notch, Hedgehog, Wingless/WNT, BMP (bone morphogenetic proteins), EGF (epidermal growth factor) and FGF (fibroblast growth factor) are primarily employed by these pathways in the eventual cascade of events. The different aberrations in such cell-signaling processes trigger the onset of respiratory diseases making the conventional therapeutic modalities ineffective. These challenges have prompted us to explore novel and effective approaches for the prevention and/or treatment of respiratory diseases. In this review, we have attempted to deliberate on the current literature describing the role of major cell signaling pathways in the pathogenesis of pulmonary diseases and discuss promising advances in the field of therapeutics that could lead to novel clinical therapies capable of preventing or reversing pulmonary vascular pathology (​https:​/​​/​www.sciencedirect.com​/​topics​/​pharmacology-toxicology-and-pharmaceutical-science​/​vascular-disease" \o "Learn more about Vascular Disease from ScienceDirect's AI-generated Topic Pages​) in such patients.











The primary role of the pulmonary system is to efficiently regulate the process of gas-exchange and maintain an equilibrium between oxygen and carbon dioxide levels in the human body. As any other systems in the human body, infections and diseases are common and characteristic with the respiratory system, especially in high risk, immunocompromised populations. It is reported that, currently, there is an upward trend in the global prevalence of chronic respiratory diseases, primarily due to increased global smoking rates, as well as persistent, increasing air pollution indices (both indoor and outdoor) and occupation-related exposures (Günther and Seyfert 2018). Multiple cell types are involved in the onset and progression of respiratory diseases, including, airway epithelial cells, parenchymal cells, immune cells, goblet cells and structural cells. Brief exposure to external particulate matter, chemicals or fumes activates the airway epithelium, which in turn releases cytokines or chemokines, that lead to further activation of the immune system, the goblet cells and other structural cell types viz; the type I and type II pnumocytes (Ornitz and Yin 2012). 
Communication among the population of cells is mediated in the form of cell-signaling, which allows the cells to respond to external and internal stimuli (Alberts et al. 2002). These alterations in the cell action are regulated by a number of chemical and mechanical signals and is achieved through specific receptors localised on the plasma membrane of the cells, which activate certain pathways to control the external signals and thus influence the overall cellular behavior (Wadhwa et al. 2019a)(Ardito et al. 2017). The cell signaling pathways involves receptors like cytokine receptors, TGF-β (Transforming Growth Factor- beta), GPCRs (G Protein-Coupled Receptors) and RTKs (Receptor Tyrosine Kinase) on their plasma membrane, which not only actuate, exercise and encrypt the external signals but also establish a connection between intrinsic and extrinsic signals (Kholodenko 2006).
Additionally, cell-signaling pathways are capable to percept the on-going activities on the cell surface and subsequently communicate the information with the surrounding cells (Thompson and Giancotti 2018). The standard terminus for cascade cell-signaling lies in the nucleus, where they regulate transcription factors, potentially leading to changes in the gene regulation and subsequent cellular responses (Samarakoon et al. 2010). For example, there are several cell-signaling responses that target the cytoskeleton and control the structural cellular responses; whereas, other signaling cascades target specific tissues (Valdespino-Gómez et al. 2015). For instance, cell-signaling that takes place within the mitochondria impacts cellular metabolism as well as determines cellular apoptosis (Jeong and Seol 2008). The PI3K/Akt, EGFRs (epidermal growth factor receptors), growth factor tyrosine-kinase receptors, MAPKs (mitogen-activated protein kinase), NADPH oxidase/ROS, PKC, PPARs (peroxisome proliferator-activated receptors) and SFKs (Src family kinase) are the main components in the signaling cascade (Refsnes et al. 2008)(Gallelli et al. 2018). Any significant alteration in these signaling processes would result in diverse respiratory ailments like asthma,  chronic obstructive pulmonary disease (COPD), etc. (Athanazio 2012)(Azarpazhooh and Leake 2006). These diseases initially affect the surrounding cells and tissues lying nearby and subsequently lead to the destruction of healthy tissues resulting in chronic inflammation (Sharma et al. 2019)(Mehta et al. 2019b)(Dua et al. 2019a)(Dua et al. 2018). This review intends to provide the scientific community with a better understanding of the different aspects of cell-signaling and their role in respiratory diseases. Additionally, this review also discusses the interactions of various pharmacological interventions with cell-signaling molecules during the pharmacotherapy of respiratory diseases.   
1.1.	Cell-signaling pathways
Cell-signaling pathways are the major cellular response regulating processes that lead to different molecular events namely; angiogenesis, apoptosis, metastasis, proliferation, and resistance development within cells (Perrimon et al. 2012). Despite their vital roles in almost all cell functions, these processes are only partially understood. Moreover, different aberrations in cell-signaling processes trigger the onset of various diseases making conventional treatment strategies ineffective (Sebastian-Leon et al. 2014). These challenges have prompted to explore new techniques and cell-signaling target agents for treating respiratory diseases. The different types of cell-signaling pathways are summarised in Fig. 1.  
 
Fig.1. Types of cell signaling pathways
1.1.1.	Wnt pathway
Wnt pathway is one of the evolutionary conserved, signal transductions pathways which control different cellular processes like cell fate, cell polarity, cell migration and organogenesis (Enzo et al. 2015). It is known that extra-cellular Wnt ligands (there are 19 known types in humans till date) trigger the different intracellular signals which further initiates the cascade reaction, involving both Wnt/β-catenin-dependent or canonical pathway as well as β-catenin-independent or non-canonical pathway (MacDonald et al. 2009). The non-canonical pathway is further classified into Wnt/Ca2+ and planar cell polarity pathway. Moreover, Wnt proteins have been found to regulate various cellular processes. In addition, it has been reported recently that such proteins play a significant role in stem cell renewal (Pataki et al. 2015). 
The canonical Wnt Pathway involves the activation of β-catenin-mediated transcription gene via Wnt ligands (MacDonald et al. 2009). However, when a particular Wnt ligand is absent, cytosolic β-catenin is firmly regulated by β-catenin destruction complex. This complex comprises of Axin protein, APC (adenomatosis polyposis coli), PP2A (protein phosphate 2A), GSK3 (Glycogen synthase kinase 3) and CK1α (casein kinase 1α). In addition, it is found to be involved in the phosphorylation and degradation of β-catenin (Stamos and Weis 2013). In order to inactivate the β-catenin destruction complex, binding of distinct Wnt ligand with frizzled (FZD) receptor is required which initiates the synthesis of low-density LRP5/6 (lipoprotein receptor-related protein 5/6). Synthesized LRP5/6 further triggers the intracellular signaling cascade, which inactivates the β-catenin destruction complex (MacDonald and He 2012). 
The non-canonical Wnt signaling depends on the binding of distinct Wnt ligand with FZD receptors but without the involvement of LRP5/6 receptors (Baarsma and Königshoff 2017). It is also known as the β-catenin independent pathway as it is involved in targeted gene expression and intracellular signaling. Hence, they have been further classified into two types i.e. a) Planar Cell Polarity (PCP) and b) Wnt/Ca2+ pathway (Lien and Fuchs 2014). The PCP pathway down-streaming reveals that RhoA regulates the organization of the cytoskeleton and cell survival. On the other hand, subsequent activation of Rac and JNK regulates the transcription of AP-1 dependent gene (Munoz-Soriano et al. 2012). The Wnt/Ca2+ pathway has been found to hinder the transcription of the gene via NFAT. Additionally, it can also obstruct the β-catenin signaling via NLK (De 2011). The Wnt signaling involves different extra-cellular factors and the co-receptors allow easy amendment of both the pathways of Wnt signaling (Sherwood 2015a). 
1.1.2.	Notch Signaling Pathway
Another highly conserved signaling pathway involved in the normal functioning in both adulthood and development stage is the Notch Signaling Pathway. This pathway is involved in cellular processes like cell lineage progression and fate determination (Sassi et al. 2011). During the division of stem cells asymmetrically, one cell turns into a daughter/progenitor cell and selects its fate to transform itself into a particular cell type. Whereas, another cell retains the fate of stem cell i.e. self-renewal (Ables et al. 2011). As the progenitor cell transform themselves in accordance with new cell fate, they employ Notch Signaling Pathway to repress neighboring cells from opting the similar cell fate. This pathway depends on the short-life mechanism and direct interaction of cells, which is the characteristic feature of this signaling pathway (Udolph 2012). Further, this pathway is also divided into two types i.e. canonical and non-canonical notch signaling pathways. In Canonical Notch Signaling Pathway, the receptors interact with extracellular ligand present on the transmembrane of contacting cell. This interaction triggers the proteolysis of transmembrane receptors and subsequent release of NICD (Notch Intracellular Domain) from the receptor. The formed NICD translocates itself to the nucleus, where further it interacts with CBF1 (C promoter-binding Factor), which is also known as KBF2 (kappa-binding factor 2 in mammals) or RBPJ- (immunoglobulin kappa J region) (Kopan and Ilagan 2009). On the other hand, during non-canonical notch signaling there is no proteolysis of notch receptor and is triggered by non-canonical ligand (D’Souza et al. 2010). 
To date only four Notch receptors (Notch 1-4) and five ligands like Delta-like (i.e. Dll1,
Dll3 and Dll4) and homologs to Serrate (i.e. Jag1, Jag2) have been identified in mammals (Andrawes et al. 2013). The notch signaling pathway has been found to be involved in the activation of the transcription process in different cells under different conditions (Nandagopal et al. 2018). Thus, it is believed to be associated with a variety of diseases. A better insight into this pathway will enable us to understand the role of Notch signaling in the pathogenesis of lung diseases.
1.1.3.	Hedgehog Signaling Pathway
Hedgehog (Hh) signaling pathway, originally studied in the Drosophila melanogaster, is a highly conserved evolutionary pathway involved in signal transduction from cell membrane to nucleus. This pathway is also known as Hh-Gli (Hedgehog-Gli), Hh-Ptch (Hedgehog-Patched) and Hh-Ptch-Smo (Hedgehog-Patched-Smoothed) pathways (Skoda et al. 2018). This pathway has been found to play a vital role in cell proliferation, embryonic development, somatic cell maintenance, tissue repair and regeneration (Jia et al. 2015). There are three main proteins that are involved in the activation of Hh signaling i.e. Hedgehog (Hh), Ptch (Patched) and Smo (Smoothed) ligands (Rubin and de Sauvage 2006). 
Hh Signaling pathway involves a cascade reaction that is triggered due to the formation of Hh-ptch1 complex. This complex further gets degraded by lysosomes, which relieves Smo inhibition. The relieving of Smo inhibition allows the Hh transmission during the downstream of Smo through cytoplasmic protein complex composed of GliFL (full-length glioma-associated oncogene), Kif7 (kinesin protein) and Sufu (Suppressor of fused) (Varjosalo and Taipale 2008). During this transmission, Smo reaches the tip of primary cilia of the cell and signals Sufu to liberate GliA (Gli activator). Then, the released GliA reaches the nucleus and initiates the expression of targeted genes. This cascade reaction involving transcription factors of Gli family is also known as the canonical Hh signaling pathway (Choy and Cheng 2012). On contrary the non-canonical Hh signaling pathway is Gli-independent. During the absence of Hh ligand, the scenario is different as Ptch moves itself to the base of the primary cilia and suppresses the Smo activity by preventing its translocation through primary cilia (Wilson and Chuang 2010). This triggers proteolysis of GliFL to GliR (Gli repressor) on the phosphorylation via CK1 (Casein Kinase 1), GSK3 (Glycogen Synthase Kinase-3) and PKA (Protein Kinase A). Then, the formed GliR binds to the promoter region of Hh target gene and switches it off (Lauth and Toftgård 2007). As Hh signaling pathway is involved in various cellular processes, it is not surprising that minor changes in this signaling pathway will not necessarily cause any pathological abnormalities like cancer. 
Lately, it has been reported that Hh has three counterparts in mammals like DHH (Desert Hedgehog), IHH (Indian Hedgehog) and SHH (Sonic Hedgehog) proteins that are involved in different cellular processes (Choy and Cheng 2012). The DHH was found to be involved with the development of germ cells of the nerve sheath and testis. The IHH was found to control the bone formation and the SHH was found to be involved with various organ development processes during embryogenesis (Briscoe and Thérond 2013). Hence, the identification of these proteins revealed their roles in different cellular processes and highlighted the effect of any dysregulation of Hh pathway.    

1.1.4.	Hippo Signaling Pathway
Hippo signaling pathway was initially discovered in Drosophila melanogaster and found to be involved in different cellular processes like apoptosis, cell growth and proliferation. This is also a highly conserved pathway and found to perform multiple functions in mammals namely regulation of cell growth and proliferation, organ size and maintenance of homeostasis in the tissues (Ramos and Camargo 2012). Moreover, this signaling pathway involves transcription factors, co-activators and kinase cascade (Meng et al. 2016). In Mammalian Hippo Signaling Pathway, merlin protein (encoded by neurofibromatosis type 2 gene) is involved which regulates the activity of first kinase protein i.e. MST1/2 (mammalian Sterile 20-like kinases 1 and 2). Then, MST 1/2 phosphorylates Lats1/2 (Large tumour suppressor-1 and -2) protein which is further controlled by MOB1 (Mps one binding protein). Here, MOB1 functions as the co-activators as it activates Lats1/2 and enhances the MST 1/2 phosphorylation process. After subsequent phosphorylation, Lats 1/2 phosphorylates the closely linked transcription factors like TAZ (transcriptional coactivator with PDZ– binding motif) and YAP (Yes-activated protein) (Pan 2010). 
After the phosphorylation of TAZ and YAP, closely-associated receptors which have specific and overlapping functions interact with TEAD (TEA domain) protein, which initiates the transcription of target genes like AR (amphiregulin), BIRC5 (Baculoviral inhibitor of apoptosis repeat-containing 5) and CTGF (cysteine-rich protein connective tissue factor) (Halder and Johnson 2011). In a few cases, phosphorylation of TAZ and YAP inactivates them and transfer them out of the nucleus. TAZ is exported out of the nucleus by the assistance of 14-3-3 protein whereas, YAP gets inactivated by ubiquitination pathway involving CKIε (casein kinase Iε) and CKIδ (casein kinase Iδ). Due to the involvement of this pathway with various metabolic processes like hexosamine biosynthesis, glycolysis and mevalonate synthesis as well as with AMPK (AMP-activated protein kinase) pathway, it makes it essential to understand the function of this pathway (Ardestani et al. 2018). Moreover, the association of this pathway with various cellular processes reveals its involvement in different pathological abnormalities especially cancer. 
1.1.5.	Akt/PKB/P13K Signaling Pathway
Akt/PKB/P13K signaling pathway is a serine/threonine-protein kinase pathway and is a member of AGC (cAMP-dependent protein kinase A/G/C) superfamily of Protein Kinases (PK). As a member of PK superfamily, there is a high similarity in the catalytic domain, as well as, in the activation mechanism. In mammals, three genes have been found to be encoding for Akt1/PKBα, Akt2/PKBβ and Akt3/PKBγ (K. Morrow et al. 2010). Moreover, this signaling pathway also plays a major role in different cellular processes like apoptosis, cell growth, nutrient metabolism and survival (Yu and Cui 2016). The action mechanism of this pathway starts with binding of ligands like cytokines, growth factors and hormones on RTK (Receptor tyrosine kinase) which activates Akt/PKB cascade reaction. The binding of ligands with RTK triggers the autophosphorylation of tyrosine residues at the intracellular end of the receptor. This enables the receptor to recruit P13K (Phosphatidylinositol 3 kinase) to phosphotyrosine residue via SH2 domain of P13K. This interaction induces the structural modification at the catalytic site of P13K, which further activates the kinase activity (Manning and Toker 2017). The activation of kinase causes the phosphorylation of PIP2 (phosphatidylinositol (3,4)-bisphosphate) and generates PIP3 (phosphatidylinositol triphosphate). The generated PIP3 further binds to Akt at PH (pleckstrin homology) domain, which allows the translocation of Akt within the membrane (Hemmings and Restuccia 2012).
PDK1 (Phosphoinositide-dependent Protein Kinase 1), which is also anchored to the cell membrane by PH domains, phosphorylate the Akt at Thr308 and partially activates it. The phosphorylation of mTORC2 at Ser473 of Akt triggers its full enzymatic potential (Yuan and Guan 2015). Other members of PIKK (P13K-related kinases) like DNA-PK also phosphorylates Akt at Ser473. On the other hand, PP2A (Protein phosphate 2A) dephosphorylates Akt (Nitulescu et al. 2018). Moreover, PTEN (Tumor suppressor phosphatase and tensin homolog) dephosphorylates PIP3 and inhibits the Akt activity (Xu et al. 2014). Therefore, Akt/PKB/P13K being the central player of signal transduction has emerged as the target signaling pathway. Any dysregulation in this pathway may lead to the development of different human disorders like cancer and cardiovascular disease (Abeyrathna and Su 2015).    
1.1.6.	cAMP-dependent Pathway
cAMP (cyclic AMP) is the pervasive secondary messenger involved in multiple cellular processes, associated with different neurotransmitters and hormones. Another name of this pathway is adenylyl cyclase pathway (Yan et al. 2016). It is associated with cellular processes like cell growth, protein expression and transcription of genes involving AMP. It is noteworthy to understand that intracellular cAMP level is regulated by maintaining the balance of two enzymes named AC (adenylyl cyclase) and PDE (cyclic nucleotide phosphodiesterase) (Fajardo et al. 2014). In mammals, about nine different adenylyl cyclases have been identified which gets stimulated by Gs proteins. The α-subunit of Gs protein is found to be coupled with various membrane receptors along with other subunits like β and γ. These β and γ subunits get dissociated in later stages on the binding of specific ligands (Sassone-Corsi 2012). Twelve different members of the PDE family have been found to involve in cAMP degradation. There are three main targets that regulate the cAMP pathway are cyclic-nucleotide-gated ion channels, guanine-nucleotide exchange factor (GEF) EPK and PKA (Nunes et al. 2014). 
This pathway gets initiated on the binding of ligands like glucagon and epinephrine with GPCR (G-Protein coupled receptor), which causes the release of subunit Gα. The release of Gα subunit subsequently activates the AC (Adenylyl cyclase) (Fimia and Sassone-Corsi 2001). Further, activated AC synthesis cAMP from ATP (Adenosine Triphosphate). The synthesized cAMP further binds with the regulatory subunit of PKA (Protein Kinase A), allowing the liberation of catalytic kinase subunits of PKA for phosphorylating the glycogen phosphorylase kinase, troponin I and stimulates the various other cell signaling pathway (Søberg and Skålhegg 2018). Therefore the involvement of cAMP in different cell signaling pathways has made it the targeted pathway. Any dysregulation in this pathway may lead to pathological abnormalities and chronic diseases especially cancer.    
1.1.7.	JAK-STAT Signaling Pathway
JAK (Janus Kinase)-STAT (Signal Transducer and activator of Transcription) Signaling Pathway, is a robust signal transduction pathway for transferring information from receptors of the cell surface to the nucleus as well as inactivating transcription gene (Seif et al. 2017). This pathway is stated to be a pleiotropic cascade as it transduces multiple signals for maintaining homeostasis and development in animals (Xu et al. 2013). Cytokines like interferons are the major components involved in the activation of JAK-STAT pathway. This signaling pathway triggers the phosphorylation process, on the interaction of cytokines with JAK-linked to the extracellular domain of the receptor. This phosphorylation reaction activates tyrosine residue on JAK receptor and generates the docking space for SH2 (Src homolog 2) domain of the STAT (Jatiani et al. 2010). On docking, SH2 domain of STAT and tyrosine residue of JAK undergoes phosphorylation to form dimerized STATs. Later, this dimerized form of STAT is imported inside the nucleus via Imp-α (Importin- α) and helps in binding of dimerized STAT to promoter region of DBD (DNA binding Domain) (Kiu and Nicholson 2012). And, this binding initiates the transcription of various target genes especially SOCS (suppressor of cytokine signaling proteins), which function as negative-feedback loop and regulates the action of JAK-STAT pathway (Rawlings et al. 2004). N-PTP (nuclear protein tyrosine phosphatase) comes into action during the termination of transcription process and inactivation of dimerized STAT of JAK-STAT pathway. Therefore, inactivated STAT gets exported out of the nucleus by CRM1 (chromosome region maintenance 1), which completes this signaling pathway (Pike and Tremblay 2016)(O’Shea et al. 2002). As this process is dependent on the interleukin and cytokines receptors, any mutation in these receptors can result as a modification in the JAK-STAT pathway. Additionally, STAT3 has been also found to be involved in the transcription of anti-apoptotic factors like Bcl-2 (Thomas et al. 2015). Therefore, the involvement of this pathway is with different cellular processes and various abnormalities. These implications of JAK-STAT path prompt us to get a better insight into this pathway for effective treatment. 
1.1.8.	MAPK/ERK Signaling Pathway
MAPK (Mitogen-activated protein kinase), is a multifunctional signaling pathway involved in different pathways regulating the cellular processes like apoptosis, cell growth, metabolism and transcription of the gene (Cargnello and Roux 2011). The final MAPK component activates the three signaling pathways i.e. ERK (Extracellular-signal regulated kinase) pathway, JNK (c-Jun-N-terminal kinase) pathway and p38 pathway (Munshi and Ramesh 2013). 
The MAPK pathway gets initiated by a specific extracellular signal which successively activates particular MAPK like MAPKKK (MAPK kinase kinases) and MAPKK (MAPK kinase) (Cobb 1999). The interaction of ligands with receptors of cell surface activates the MAPKKK by phosphorylating downstream protein kinase. The activated MAPKKK directly phosphorylates the MAPKK, which subsequently activates the MAPK via phosphorylating the TxY motif (Roskoski R 2012). Once, the phosphorylation of different substrate start taking place in the cytoplasm and nucleus it induces changes in gene expression and protein function which further triggers the specific biological response (Arthur and Ley 2013). MAPKs have a docking site for the binding of the substrate. In addition, MAPKKs allow effective P-P (protein-protein) interaction. This high-affinity P-P interaction confirms that activation takes place because of specific upstream MAPKK, which further recognizes the particular downstream targets (Cargnello and Roux 2011). 
Additionally, RTKs (Receptor tyrosine kinases), GPCRs (G-protein coupled receptors), integrins, small GTPases (Ras and Rap), Raf family, Mos, and Tp12 are found to be involved in this pathway (Keshet and Seger 2010). Due to the involvement of this pathway in different cellular processes and interlink between other cell signaling processes has prompted to understand the mechanism for successful treatment. Minor modification and dysregulation may lead to the development of cancer. 
1.1.9.	TGF-β Signaling Pathway
TGF-β (Transforming growth factor - β) Signaling pathway is involved in different cellular processes like apoptosis, cell proliferation, differentiation and regulating different biological responses (Zhang et al. 2017b). Generally, this pathway gets triggered on the oligomerization of receptors of serine/threonine kinase or due to the phosphorylation of Smad2/3 of activin/TGF-β. These phosphorylated Smads activated by receptors of plasma membrane receptors causes the recruitment of Smad4 (signal transducer) (Hata and Chen 2016). These signal transducers interact with specific transcription factors for transcription of a specific gene. Additionally, there are few I-Smads (Inhibitory Smads) like Smads 6/7, which function in the negative feedback loop (Moustakas et al. 2001).
Moreover, MAPK also gets regulated by TAP-1 (TGF-β-activated kinase-1) at different cellular or signaling level. Therefore, TGF-β is also found to be involved in various other pathways like p38, Erk and JNK pathway. Along with this, elevated expression of TGF-β 1-3 is found to be associated with malignant glioma formation. Hence, TGF-β is believed to directly involved in tumor formation, reduce anti-tumor activity of the immune system and self-renewal of glioma cells (Zhang 2009).
1.1.10.	TLR Signaling Pathway
TLR signaling is mainly involved during innate immunity response. It involves toll-like receptors having PRRs (Pattern Recognition Receptor) domain which is usually present on dendritic cells, epithelial and fibroblast cells (Jang et al. 2015). The TLRs are capable to recognize PAMPs (Pathogen associated molecular pattern) and DAMPs (Damage associated molecular pattern). PAMPs include cell-wall components like lipoprotein, lipopeptides, peptidoglycan, and flagellum, whereas, DAMPs include Hsps (Heat shock proteins) as well as protein fragments of ECM (Extra Cellular Matrix) (Feng and Chao 2011).
In Humans, ten different members of TLRs (i.e. TLR1-TLR10) have been identified. These TLRs are either present on the surface of a cell or intracellular components like endosome, endoplasmic reticulum and lysosomes (Goulopoulou et al. 2016). TLRs on cell surface generally recognize the components like proteins, lipids, and lipoproteins of microbes. Whereas, intracellular TLRs recognize nucleic acid of bacteria/viruses and sometimes, they also recognize the host nucleic acid under disease conditions like autoimmunity (Pandey et al. 2015).
The initiation of the TLR signaling takes place from TIR (Toll/IL-1 receptor) domain which is linked to MyD88 (TIR-domain containing adaptor). The interaction of ligands with TIR and MyD88 recruits IRAK-4 (IL-1 receptor-associated kinase-4) where IRAK-4 phosphorylates the TRAF6 (TNF Receptor Associated Factor 6) (Troutman et al. 2012). The phosphorylated TRAF6 further activates the IKK complex and activated IKK complex triggers MAP kinase pathway (Cohen and Strickson 2017). TLRs are associated with different cellular and signaling pathways that make it a targeted entity for treating chronic and pathological diseases.  
1.1.11.	VEGF Signaling Pathway
VEGF (Vascular endothelial growth factor) pathway is one of the important signaling pathway that controls the functioning of epithelial cells like permeability, synthesis of vasoactive molecule, vascular tone and mitogenesis (Harmey et al. 2004). This signaling pathway is mainly regulated by VEGF, which is produced by cells like inflammatory cells, fibroblasts and various types of tumor cells (Shibuya 2011). VEGF family is composed of structurally similar factors like VEGF A/B/C/D and PIGF (Placenta Growth Factor) (Holmes and Zachary 2005). The whole signaling pathway is regulated by three receptors of tyrosine kinase i.e. VEGFR-1/Flt-1 (fms-like tyrosine kinase-1), VEGFR-2/Flt-1 /KDR (kinase insert domain-containing receptor) and VEGFR-3/Flt-4 (fms-like tyrosine kinase-4) (Shibuya 2013).
This pathway elicits the binding of a ligand to the extra-cellular domain of the receptor, which triggers the dimerization and autophosphorylation of particular intracellular tyrosine residues. Later, these phosphorylated tyrosine residues recruit different intracellular proteins like PLC-γ (Phospholipase C- γ), Sck (Shc-like protein) and VRAP (VEGF-associated protein) via SH2 domain and activate the protein through phosphorylation (Simons et al. 2016). Moreover, activation of PLC- γ causes the hydrolysis of PIP2, which stimulates the production of secondary messengers like DAG (sn-1,2-diacyl glycerol) and IP3 (Inositol (1,4,5)-triphosphate). Further, DAG functions as the activator of PKC (Protein Kinase C) and IP3 is involved in the liberation of intracellular Ca2+ ions by binding to a particular receptor on ER (Endoplasmic reticulum) (Karali et al. 2014). Various other proteins like FAK (focal adhesion kinase), p38 MAPK (p38 Mitogen-activated protein kinase) and P13K (Phosphoinositide 3-kinases) are also involved in this pathway (Claesson-Welsh and Welsh 2013). The signal transduction of this pathway performs cellular functions like cell proliferation, migration, permeability and survival. On the other hand, abnormal functioning of VEGF is involved in the development of diseases like atherosclerosis and hyperthyroidism (Park et al. 2018). Additionally, VEGFs are the chief mediator of angiogenesis responsible for proliferation and metastasis of tumor. The involvement of this pathway in tumor progression and tumorigenesis makes it an attractive target for developing pharmacotherapy for cancer (Zuazo-Gaztelu and Casanovas 2018).








Fig. 2. The unified hexagonal view of various cell-signaling pathways. The numbers (1-11) in the figure represents - 1- Wnt-Signaling Pathway,  2- Notch Signaling Pathway, 3- Hedgehog Signaling Pathway, 4- Hippo Signaling, 5- Akt/PKB/P13K Signaling Pathway, 6- cAMP Signaling Pathway, 7- JAK-STAT Signaling Pathway, 8- MAPK Signaling Pathway, 9- TGF-β Signaling Pathway, 10- TLR Signaling pathway and 11- VEGF Signaling Pathway respectively.
1.2.	Synergism between Cell Signaling Pathways & Respiratory Disorders
1.2.1.	Lung cancer and cell signaling
 	WNT signaling pathway is well known for regulating the growth of tissues, specifically lung development. The importance of WNT signaling in the establishment of lung cancer is well known (Sherwood 2015b). Lung cancer can be divided into two types: small cell lung cancer and NSCLC (Non-Small Cell Lung Cancer). These two forms are responsible for 20% and 80% of all lung malignancies (Sharma et al. 2019)(Dua et al. 2019b)(Mascaux et al. 2017). The oncogene progression undergoes different steps, which leads to the development of healthy epithelial cells into malignant cells (Lee et al. 2018). Impaired WNT signaling has been studied in NSLC and colon cancer. The dynamic WNT signaling is carried out by an increased expression of DVL, which is an intracellular signal transducer. DVL3 is highly expressed in NSLC specimens. Blocking DVL would cause the lowering of β-catenin and thus cell growth was decreased (Gammons et al. 2016). The mediators of WNT signaling pathway- WIF, Sfrp1 and DKK3 are downregulated in NSLC and other forms of cancer (Stewart 2014). Hypermethylation of promoters leads to shut-down of transcription mechanism and thus results in the downregulation of WNT mediators (Ng and Yu 2015). 
Mutation in WNT signaling genes like APC or β-catenin is constantly linked with colon cancer, while these gene mutations are scarce in lung cancer (Schatoff et al. 2017). Studies have found an imbalance of WNT signaling proteins in NSLC samples. WNT 1 signaling protein express overly in NSLC specimen and apoptosis treatment in cancer cells expressing this signaling protein was ineffective (Zhan et al. 2017). Contrarily, by blocking the WNT signaling protein, apoptosis was regulated in human cancer cells which resulted in the diminished tumor in in-vivo and in-vitro conditions (Ding et al. 2016). Similarly, WNT 2 signaling protein is highly expressed in NSLC and its inhibition leads to apoptosis of cancer cells. The overexpression of WNT 5a signaling protein is linked with more dangerous NSLC. While WNT 1,2,5a are overexpressed in NSLC, the expression of WNT7a is lowered (Rapp et al. 2017)
A wide range of therapy are currently available for the management of lung cancer along with the advancement in  understanding of the pathogenesis of cancer biology (Garg et al. 2016; Bakshi et al. 2019; Wadhwa et al. 2019b; Aljabali et al. 2020). These therapies are prescribed to the patient according to cancer type, stage of cancer, the extent of metastasis and particular gene expression. Lung cancer therapy are broadly classified into chemotherapy, targeted therapy, immunotherapy, and combination therapy (Liu et al. 2018). Chemotherapy is a first line treatment for the advanced stage of lung cancer, showing an advantage for patients compared to palliative care. In lung cancer patients, chemotherapy can increase survival by inhibiting the proliferation of tumor cells. Cisplatin, gemcitabine, paclitaxel, docetaxel, carboplatin, doxorubicin is used as a chemotherapy in lung cancer and various scientific research has been conducted as well as ongoing to explore their efficacy and advantage over other options (Garbuzenko et al. 2010; Mangal et al. 2017; Dua et al. 2019c).  Even though platinum-based chemotherapy is regarded ideal for the advance stage of NSCLC without mutation of known gene, targeted therapy is becoming apparent to significantly improve patient outcomes in terms of survival with quality of life (Dua et al. 2019c). Immunotherapy is another emerging therapeutic option with multiple ongoing clinical trials for lung cancer patients. Some the results are robust showing evidence of positive response during treatment and trials. Different immune checkpoints inhibitors such as atezolizumab, nivolumab, durvalumab, pembrolizumab, avelumab targeting programmed cell death protein 1/program cell death-ligand 1 (PD-1/PD-L1) pathway are in clinical trial. It is very important to establish the site of immune deficiency and protocols to correct those deficiency in patients (Dine et al. 2017; Hendriks et al. 2018; Ribas and Wolchok 2018). PD‐1/PD‐L1 inhibitors exhibit three typical characteristics; a) they specifically target tumor microenvironment, b) they can normalize tumor immune response, and c) they can control the immunity in tumor microenvironment. Due to advancements in technology and cancer biology, various oncogenic drivers are now recognized and based on these drivers, targeted therapies are being studied and developed. 
Targeted therapies are critical to control lung cancer progression and can be administered as initial therapy. Currently, targeted therapy is appropriate for typical gene mutations prevailing in NSCLC and these include tyrosine kinase inhibitors, drugs targeting epidermal growth factor receptor mutations (e.g. erlotinib, gefinitib, afatinib), anaplastic lymphoma kinase and receptor tyrosine kinase mutation (eg.  crizotinib) (Chan and Hughes 2015). Another common therapeutic practice in oncology is use of combination therapy. Various medicines are administered together as a combination therapy in lung cancer. This includes a combination of carboplatin-paclitaxel, nivolumab with platinum doublet, cisplatin-etoposide-irinotecan to reduce the noxious side effect, achieve synergistic effects and favorable outcomes. The combination therapy can amplify treatment efficacy by additive effects as compared to the efficacy with monotherapy. The amalgamation of medicine can also reduce the probability of drug resistance as well as provide the greatest therapeutic benefit such as inhibiting cancer cell growth and metastasis, reducing cancer stem cell population and inducing cancer cell apoptosis/death (Mokhtari et al. 2017).
1.2.2. COPD (Chronic Obstructive Pulmonary Disease) and cell signaling
The population of individuals suffering from COPD suffering individuals is widespread. It is the third most common reason of death worldwide and the third in the UK and various developed nations. It is placed at a fifth position to cause impairment as around 10 percent of the population over 45 years are influenced by it (Mehta et al. 2019a) (Quaderi and Hurst 2018). Cigarette smoking is the most common cause behind COPD in developed countries, capturing both men and women, which depicts an equal level of smoking among both sexes (Laniado-Laborin 2009). Whereas, in developing countries, COPD is majorly caused by wood/biomass smoke and rarely by cigarette smoke. The symptoms associated with COPD are- small airway disease and emphysema (Capistrano et al. 2017). 
Akt is the intermediator to a cellular mechanism that contributes to COPD infection. Akt encourages the existence of inflammatory cells in in vivo conditions (Zhang et al. 2013). In COPD, there is persistent exposure to smoke and respiratory pathogens, Akt functions for a long period of time, which results in an increase in the existence time for inflammatory cells and hence homeostasis is broken, thus leading to impaired lung functions and pathology (Tang et al. 2018). 
The P13K complex is placed at the plasma membrane by ligand-facilitated induction of numerous receptors. P13K (lipid kinase) acts as a catalyst for the generation of phosphatidylinositol-3,4,5-phosphate (Bhattacharya et al. 2016). PTEN is a lipid phosphatase that controls the production of phosphatidylinositol-3,4,5-phosphate by converting it to phosphatidylinositol-3,4-phosphate. PTEN works as a docking molecule for Akt and its activator PDK-I. Akt is triggered by PDK-I by phosphorylating critical T-loop residue (Threonine- 308). The induced Akt is liberated from the membrane which targets various substrates and has a specific role in apoptosis, inflammation and proliferation. Dephosphorylation of protein phosphatase 2A leads to the inactivation of Akt (Sugiyama et al. 2019).
The inflammation in COPD is observed in the lung parenchyma and surrounding airways. Inhaled cigarette and biomass smoke induce macrophages and epithelial cells to liberate certain chemotactic constituents which directs inflammatory cells towards the lungs (Barnes 2016). The CCL2 chemotactic factor reacts to CCR2 in order to direct monocytes. Similarly, CXCL1 and CXCL8 reacts to CXCR2 and directs monocytes and neutrophils. CXCL9,10,11 reacts to CXCR3 to attract Th1 and Tc1 (type 1) cells (Kuo et al. 2018). Macrophages liberate Il-23 to act on TH17 cells which release IL-17 and encourages inflammation mediated by neutrophils. The epithelial cells, inflammatory cells and macrophages liberate proteases like MMP9 which leads to emphysema and disrupt elastin (Bozinovski et al. 2015). Macrophages and epithelial cells liberate TGF-β, leading to multiplication of fibroblast and by the liberation of CTGF, fibrosis is induced around small airways. Neutrophil elastase causes hypersecretion of mucus (Sheppard 2015).
There are number of therapeutic options prescribed for COPD. Among these bronchodilators (example: β2-agonists and anticholinergics) are effective in the management of mild COPD and as maintenance therapy for moderate COPD (Welte 2009). The pharmacological approach for COPD patients should aim to relieve symptoms, decrease the exacerbations and restore normal body functions. In general, β2-agonists are appropriate initial therapy for the management of stable COPD (King Han et al. 2016). For immediate relief of symptoms, short-acting bronchodilators are a drug of choice. Alternatively, a long-acting inhaled bronchodilator or theophylline can prevent the further worsening of symptoms.  However, if the symptoms are more severe or if a patient is at risk of developing chronic exacerbations (eg: patient categorized in B, C, D by global initiative for chronic obstructive lung disease), long-acting bronchodilators are preferred over short-acting bronchodilators (Barjaktarevic et al. 2015; Bishwakarma et al. 2017). According to the response and preference of patients, the second-line drug is determined (Chong et al. 2012; Farne and Cates 2015). Tiotropium is an anticholinergic long-acting medicine commonly recommended as maintenance therapy for COPD patient with moderate severity. Slow disassociation of tiotropium from the muscarinic receptors (M1 and M3) makes it ideal for long acting therapy and provides bronchodilation for > 24 hours (Barnes 2000). In comparison, long-acting β agonists (LABA) have an extended duration of effect (more than 12 hours) than short-acting β agonists (SABA) (4–6 h), (Mahler et al. 2002; Hanania et al. 2005; Dahl et al. 2006). The concept of dual bronchodilators (combining LABA and a long-acting muscarinic antagonist (LAMA) in the same inhaler device) is also available (Cohen et al. 2016). These dual bronchodilators are efficient in improving lung function, dyspnea, exercise capacity and reducing COPD exacerbations (Wedzicha et al. 2016). Choi et al. found that treatment with combination therapy of tiotropium and ICS for over 6 months improves dyspnea, lung function and reduce exacerbations in COPD patients. Similarly, a combination of ICS/LABA (salmeterol/fluticasone or budesonide/formoterol) also reduces exacerbation and improve lung function as compared to LABA alone (Calverley et al. 2003a, b, 2007). In a randomized trial, it was evident that the addition of tiotropium to other therapy for COPD decreases the exacerbations rate by 19% compared to placebo control in moderate to severe COPD (Niewoehner et al. 2005). Although these drugs are effective in reducing COPD exacerbations, there exists a risk of developing pneumonia with the use of ICS component (Chong et al. 2012). Similarly, results of some trials are contrasting as some showed that patients are given a combination of LABA-LAMA had reduced exacerbations compared to LABA-ICS combination (Wedzicha et al. 2016), while another study others found no significant difference among these combinations (Rabe et al. 2008). Therefore, more research is necessary to make a valid conclusion and guidelines for the treatment of COPD. 
1.2.2.1 Emphysema and cell signaling
Clinically emphysema is characterised as the expansion of the lungs in adults. In the new-born, it is defined as damaged alveolarisation during growth (Boucherat et al. 2016). Emphysema dominantly occurs usually in the ages between 45 and 60, as part of COPD in smoking individuals (Liu et al. 2015). Apart from this damage due to emphysema was also observed in HIV and hypersensitive- pneumonitis individuals (Staitieh and Guidot 2014). The individuals with emphysema possess reduced signaling of wnt and β-catenin, which ultimately lowers the expression of their corresponding genes (Shi et al. 2017). Wnt-5A and 5B ligands are the regulators of non-canonical wnt-signaling pathways (Komiya and Habas 2008). It has been recommended that the transition of canonical Wnt-signaling to non-canonical Wnt-signaling contributes to COPD and specifically emphysema (Baarsma and Königshoff 2017). The decreased activity of wnt/ β-catenin, c-Myc, cyclin D1, c-Jun and MMP7 contributes to deficiency of mesenchymal cells which subsequently reduces the level of extracellular matrix proteins and destruction of alveolar cells and thus leads to emphysema (Hussain et al. 2017). The inflammation in emphysema is contributed by the regulation of the innate and adaptive inflammation activities (Rovina et al. 2013). Apart from inflammation, oxidative stress generated by smoking also contributes to emphysema (Domej et al. 2014). The dominant role behind the oxidative stress is of the NF-kB, which stimulates the transcription of proinflammatory cytokines (Oeckinghaus and Ghosh 2009).
Emphysema is a persistent, obstructive, and often progressive, debilitating condition of the lungs. Cigarette smoking and air pollution are the primary factors of human emphysema. Emphysema is the widening of the adult lung's airspace. Contrary to neonatal lung alveolarization with a developmental impairment. The French physician Laennecb in the 19th century coined the definition of emphysema in which he stated that "markable differences of air vesicle size which could be smaller than the millet or the size of a cherry or haricot plant." Emphysema is the most common component of COPD in smokers between the ages of 45 and 60. 
Nevertheless, in other Non-smoking-related conditions, including HIV-1 infection, lung damage has also been reported (Sahebjami et al. 1992). Lymph follicles have been found in the parenchyma or dendritic cell infiltration and Th1 cells, raising questions regarding the nature and potential function of the immune response in emphysematous destruction. A contemporary pathogenetic emphysema model was based on data from various labs around the globe. This model notes that the elastin scaffolding of alveolar spaces is damaged enzymatically by neutrophil elastases and matrix metallopeptidase-12 (MMP-12) produced by active macrophages. Nonetheless, protease development is not exclusive to inflammatory cells; structural cells, including epithelial and endothelial cells, may generate proteases as well (Mercer et al. 2004). Elastin fragments are considered as chemotactic in-turn and attract inflammatory cells to the site of wounds, thus showing that inflammatory cells and proteases play an essential role together, thus protecting individuals from cigarette-induced emphysema (Ofulue and Ko 1999). While the involvement of inflammatory cells that can release oxidants and proteases is now well known, it has been recorded that a range of acute lung diseases can develop and cure fully without emphysematous damage with significant inflammation (like bacterial pneumonia and acute lung injury). Innate immune depends on molecular structural recognition receptors, which are familiar to many micro-organisms, like Lipopolysaccharide Receptor (LPS), and endogenous ligands, such as heat shock proteins. Toll-Like Receptor 4 (TLR-4) activation by LPS allows both cytokines and reactive oxidant species to be formed. Lung cytokines alterations, oxidant stress, and TLR signage were all linked to the experimental emphysema. Recent interest has been shown to sphingolipids as they find elevated concentrations of ceramides with long-chain in human emphysema, elevated ceramide rates with the VEGFR rat blockage, emphysema, and apoptosis inhibition, accompanied by the use of anticeramide neutralization. In this case, Sphingosine-1 phosphate could be a soothing surviving element throughout comparison to proapoptotic ceramides (Petrache et al. 2005).  T-Lymphocytes CD4+ and CD8+, as well as B cells also distributed in lymphatic follicles, are disproportionately present in the emphysematous lung. In a remarkable number of experiments, they have shown that IL-4 overexpression has had an impact on the lung TGF-β1 and TAO levels and reduced adenosine deaminase activity, which have caused an adenosine level to grow. In this context, IL-4 overexpression has not been due to excess of Th2 cytokines but to adenosine. Ironically, defective mouse lungs include adenosine deaminase, inflammation, and alveolar area enlargements. Furthermore, it has been reported that β-catenin, TCF, and Frizzled-4 are typically decreased compared to healthy donors in patients with pulmonary emphysema. Whereas, By comparison, by pulmonary emphysema cases, Wnt4, Wnt5a, Wnt5b, or Wnt10b was increased.
The standard treatment of emphysema includes the following regime: Bronchodilators medications (Beta-agonists and Anticholinergics, or antimuscarinics ) can help to relieve asthma, respiratory failure, and respiratory problems by relaxing of compressed airways. Corticosteroid drugs (fluticasone) inhaled as aerosol sprays can decrease inflammation and reduce breathability. 
1.2.2.2	Chronic bronchitis and cell signaling
COPD consists of a group of diseases, including chronic bronchitis and emphysema. The majority of the patients have signs of both chronic bronchitis and emphysema. Chronic bronchitis is characterized by a chronic cough. Sputum production may continue from three months to two consecutive years (Kim and Criner 2013). It also compromises of lung functioning, decreased health-related quality of life and thus leads to inclined death-rate of suffering individuals (Brown et al. 2010). The frequency of chronic bronchitis is more in individuals suffering from COPD. A study conducted on 1711 Finnish individuals for a period of 30 years suggested that chronic bronchitis was found to be 42% in regular smokers, 26% in those who left smoking and 22% in those who do not smoke. Smoking is the primary factor behind the pathogenesis of chronic bronchitis. Occurrence apart from this other factor may include exposure to chemical fumes, biomass fuel, and dust. Inflammatory responses lead to increased production of mucus by the goblet cells and subsequently lower mucus removal rate from the airways, which is characterised as chronic mucus hypersecretion (Kim and Criner 2013). A study has shown the possible involvement of FZD8 in chronic bronchitis. They have found the relationship among cytokine-mediated expression of FZD8 and chronic mucus hypersecretion, which is the effect of chronic bronchitis. It is notable that this association was unfettered by COPD which signifies the role of FZD8 in chronic mucus hypersecretion in healthy smokers. The purpose of FZD8 in increased expression of Wnt-5A and 5B in fibroblast is well known (Spanjer et al. 2016).
Moreover, Wnt-5A triggers the liberation of CXCL8 from human neutrophils, and thus Wnt-5A and 5B are of interest as ligands for FZD8 in chronic bronchitis (Kumawat and Gosens 2016). The previous statement is supported by the finding that Wnt-5A and 5B trigger the liberation of IL-6 and CXCL8 from lung fibroblasts (van Dijk et al. 2016). On the whole, the study suggests that FZD8 is a pro-inflammatory factor during chronic bronchitis.
The persistent mucus generating cough characterizes chronic bronchitis, a lung condition contributing to reduced breathing, during a substantial time as a result of inflammation of the bronchial tubes. Bronchitis can be defined as an inflammation of the bronchial tubes that triggers a cough that often produces mucus. It is noteworthy mentioning that in the lung tissues of patients with lung emphysema, the secreted frizzled associated protein 1, a Wnt inhibitor, is that, whereas Frizzled-8 is upregulated in patients with chronic bronchitis (Foronjy et al. 2010). This is consistent with the conclusion that FZD-8 is pro-inflammative in mucus hypersecretion, as MUC5AC expression is enhanced during chronic bronchitis (Spanjer et al. 2016). In comparison, the presence of cigarette smoke reduces Wnt/β-catenin signaling function in both bronchial and rodents. Treatment with the β-catenin activator SB216763 significantly reduces the cigarette smoke extract secretion in the bronchial epithelium by modulation of the pathway of PPAR β and p38 MAPK from inflammatory cytokines TNF-α and IL-1β (Guo et al. 2016). Potent angiogenesis and vascular penetrability regulator, the endothelial growth factor (VEGF), whose expression is triggered by HIF-1α. The VEGF has shown its role in pathogenesis, and chronic bronchitis can be characteristic of HIF-1α-regulating VEGF overexpression (Lee et al. 2014). In tissue remodeling and angiogenesis, COPD, VEGF, and VEGFR-1 and VEGFR-2 reactors (KDR / Flak-1) could also play a role (Lee et al. 2014). Besides, A specific signaling pathway is known to be a significant control for the preference of both alveolar macrophages and mortality, the mitogen-activated protein kinases (MAPK). Since infections with the virus have triggered most bronchitis cases, antibiotics do not function. Nonetheless, it is recommended to prescribe an antibiotic if there is suspicion of bacterial infection. Under certain conditions, prescribe certain medicines, such as cough medications. The doctor will prescribe an inhaler and other drugs to reduce inflammation and clear restricted pathways in case the patient has allergies, asthma, or chronic obstructive pulmonary (COPD) disease (Zhang et al. 2019).
1.2.2.3	Role of Oxidative Stress in cell signaling
Oxidative stress refers to the difference in cell and tissue between levels of oxidants and antioxidants for the sake of a pro oxidant system (Kalyanaraman 2013; Bernardo et al. 2015). An oxidant is an oxidation-producing compound, and an antioxidant is a molecule that either inhibits oxidation or inhibits its formation. The oxidative stress is caused by the failure of innate antioxidant processes to neutralise endogenous or exogenously created oxidants which cause an imbalance between oxidants and antioxidants. As a result, oxidants predominate and chronic oxidative stress occurs, leading to changes in lipids, proteins and DNA (Rahman 2005; Biswas et al. 2013).
Oxidative stress refers to the difference in cell and tissue between levels of oxidants and antioxidants for the sake of a pro oxidant system (Kalyanaraman 2013; Bernardo et al. 2015). An oxidant is an oxidation-producing compound, and an antioxidant is a molecule which either inhibits oxidation or inhibits its formation. The oxidative stress is caused by the failure of innate antioxidant processes to neutralise endogenous or exogenously created oxidants which cause an imbalance between oxidants and antioxidants. As a result, oxidants predominate and chronic oxidative stress occurs, leading to changes in lipids, proteins, and DNA (Rahman 2005; Biswas et al. 2013).
The long-term rise in oxidative stress is an important factor in the development of both airway and systemic inflammations in COPD and it is understood that COPD and its comorbidity are a key factor in the beginning and growth (Montuschi et al. 2000; Kirkham and Barnes 2013; Barnes 2016). Specific damage occurs as a result of both pulmonary and systemic inflammation, oxidants present in cigarette smoke and from excessive ROS and reactive nitrogen species (RNS). High levels of oxidative stress markers (e.g., superoxide and malondialdehyde) in the airspace, sputum, breathing, lung and blood in patients with COPD are reflected in increased production of ROS in airways (Rahman 2005; Stanojkovic et al. 2011). These concentrations of oxidative stress have also increased dramatically during COPD exacerbations (Antus et al. 2014).
1.2.3.	Asthma and cell signaling
Asthma is characterised as chronic inflammation of the lungs, leading to structural alterations known as airways remodelling. Airway remodelling refers to constriction of bronchi, elevated mucus generation and eosinophilia (Fehrenbach et al. 2017). The pathogenesis of asthma relies on the interaction of IL-4 and IL-13 cytokines with associated receptors. IL-4 and IL-13 interact with common receptor constituent IL-4Rα. This receptor constituent is necessary for cytokines to perform signal transduction. IL-4Rα combines with different subunits to generate heterodimer complex of receptor which is specific for ligands and perform different functions (Gour and Wills-Karp 2015). Type 1 IL-4R, is the complex of IL-4Rα and γc, is specific for IL-4 and majorly found in hematopoietic cells. Whereas type II IL-4R, is the complex of IL-4Rα and IL-13Rα1, for binding of IL-13 and IL-4, and found on hematopoietic and non- hematopoietic cells like epithelial cells of airways (Gandhi et al. 2015). 
IL-4 has a significant part in mediating asthmatic conditions (Chen et al. 2013). In mice, the integrated expression pattern of IL-4 (inferior range) and IL-13 in lung tissues, leads to various pathophysiological changes, which acts as a diagnostic measure for asthma. By deleting the genes coding for 1L-4Rα or inhibiting IL-13 expression, makes the mice resilient to initiate allergic asthma (Bao and Reinhardt 2015). Adoptive transfer research with the help of genetically defected mice and Th-2 cells (for a particular antigen) unveil that expression of IL-4Rα, on antigen encounter was vital for asthma progression (Perona-Wright et al. 2010). From other studies, it was found that on stimulating asthma conditions experimentally, mucin overexpression and goblet cell metaplasia was critically subjected to IL-4Rα and unaffected to the mast cell, eosinophils and 1L-5 (Hayashi 2012).
The primary aim of therapeutics agents for asthma should be the management of symptoms as well as the prevention of any exacerbations. At present, the standard guideline for the management of all asthmatic patients is to give a rescue therapy with a SABA inhalers whereas for persistent asthma, a low-dose of inhaled corticosteroids (ICS) is suitable. In the case of moderate-to-severe persistent asthma leukotriene inhibitors (example: montelukast) or theophylline or LABA are commonly added to the ICS therapy. Finally, if the above-mentioned therapy fails to adequately manage asthma, oral corticosteroids (e.g. prednisolone) are added (Buhl et al. 2006). ICS are effective in controlling asthma exacerbations (Juniper et al. 1990; Dahl et al. 1993). A low dose of budesonide aerosol can reduce exacerbation by 50% in a new-onset, untreated asthma (Pauwels et al. 1997; O’Byrne et al. 2001). Pauwels et al, revealed that in uncontrolled asthma patients taking a moderate dose of ICS could be benefited from high-dose of budesonide by reducing the severity of asthma exacerbation by 50% as compared to low-dose ICS treatment (R). Similarly, O’Byrne et al, showed that in uncontrol asthma patients with low dose ICS, increasing the dose of budesonide by two times reduced the exacerbation by 30%. However, the extent of protection was slighter compared to patients who newly started ICS (O’Byrne et al. 2001). In general, ICS can decrease exacerbation by 55%. ICS are superior to leukotriene antagonist and they can reduce exacerbation in children too (Covar et al. 2008). As compared to ICS therapy alone, the combination therapy of budesonise and LABA: formoterol can remarkably decrease asthma exacerbation in patient with uncontrolled asthma along with with the previous history of exacerbation (Palmqvist et al. 1997, 1999; Pauwels et al. 1997). The combination therapy of ICS and formoterol provides better relief from asthma exacerbation. Formoterol shows a quick onset of action along with good safety profile and efficacy compared to salbutamol. Leukotriene antagonists such as montelukast decrease asthma exacerbations in both adults and children (Bjermer et al. 2003; Johnston et al. 2007).  A randomized control trial compares the effect of combination therapy of leukotriene inhibitors (montelukast) and ICS (budesonide) with a double dose of ICS. This study found no significant difference in terms of exacerbation rates and asthma free days (Price et al. 2003). Tiotropium is an anticholinergic FDA approved drug that can decrease the occurrence of asthma exacerbations and beneficial for long-term management of persistent asthma in patients ≥ 6 years of age. Adding 5µg of tiotropium to ICS/LABA for patient with severe asthma can decrease the exacerbation by 21% and extend the first exacerbation time by 56 days compared to placebo (Kerstjens et al. 2012). Tiotropium has shown to reduce the frequency of asthma exacerbations in patients suffering from moderate symptomatic asthma and already in a therapy of medium-to-high doses of ICS mono therapy or ICS/LABA combination therapy. Taken together, asthma exacerbation can be managed by ICS, ICS/LABA, leukotriene antagonist, anticholinergic drugs. 
1.2.4.	Cystic Fibrosis and cell signaling
Cystic fibrosis is a persistent inflammatory condition that affects the reproductive, respiratory and gastrointestinal systems (Santibañez et al. 2011). The genetic basis of the disease is caused by the mutation in the CFTR (Cystic Fibrosis Transmembrane conductance Regulator) gene (Rowe and Verkman 2013). The gene is primarily expressed in myeloid, RBCs and numerous epithelial cells. It is estimated that around 1800 mutations have been recognised, but only a few of them account for their significance with the disease. The frequently encountered variation among the majority of the diseased individuals is the deletion of the phenylalanine at the 508th position. The product of this mutation leads to an unhealthy condition that is related to the inability to transport the mutated product to the plasma membrane. The other significant variation is the deletion of glycine at 551 position, which accounts for disrupted ion-channel functioning. From here, we can say that CF leads to numerous conditions that not only disrupt the ion-channel but also alters the protein homeostasis (Davies et al. 2005).
The protein, NF-kB accounts for the regulation of DNA transcription. It is responsible for the on-time abortion of inflammation. In individuals with CF condition, this on-time abortion is disrupted, which leads to prolonged stimulation of the NF-kB, causing an increased level of chronic inflammation and thus affecting the functioning of the lungs (Zhang et al. 2017a). In a healthy cellular environment, the NF-kB is non-functioning by its binding with inhibitor IkBα (Wardyn et al. 2015). The pathogens activate TLR or TNF receptors, which further initiate the signaling cascade and ultimately disrupt the inhibitor IkBα (Barton and Medzhitov 2003). The unbound NF-kB moves to the nucleus and triggers the pro-inflammatory genes, p50 and p65. P50 and p65 which prolong the inflammatory condition with the liberation of inflammatory cytokines (Mussbacher et al. 2019). During the signaling cascade, numerous signal transduction pathways are triggered, such as MyD88 and TRAF 2, six proteins, identified as receptors having ubiquitination (Walsh et al. 2015). Heightened levels of proficient- inflammation regulators such as IL-6, IL-8, arachidonic acid, and TNF-α were found in CF individuals (Fagerberg et al. 2014). Persistent inflammation in CF individuals is also regulated by a decreased level of anti-inflammatory molecules namely IL-10 and lipoxin (Philippe and Urbach 2018). 
Numerous miRNAs were found to be uncontrolled in CF individual’s lungs on comparing with the lungs of a healthy individual (Sessa and Hata 2013). The number of desynchronised miRNAs impacts the function of the immune system in CF individuals. Some studies link the emergence of CF diseased conditions with desynchronised miRNAs. The downregulation of miRNA in CF conditions links with increased expression of TOM1 in bronchi of CF individuals. TOM1 negatively controls the IL-1R1, TLR2, and TLR4 signaling. The increased expression of TOM1 in lungs of CF individuals is connected to prevent the persistent inflammation. It is also reported that the decreased expression of miR-17 and 93 was observed in bronchial epithelium of CF individuals (Mckiernan and Greene 2015). These miRNAs were found to aim IL-8. IL-8 is a persistent-inflammatory chemokine, whose increased expression was observed in the lungs of CF individuals (Oglesby et al. 2015). In the above-discussed literature, the decreased expression of miR-17 and 93 in bronchial epithelial cell lines, was mediated by Pseudomonas, leading to increased expression of IL-8 (Fabbri et al. 2014).
FDA has approved nintedanib and pirfenidone as a therapy for the treatment of idiopathic pulmonary fibrosis (IPF). Although these drugs slow down the disease progression, they are not able to completely cure the disease (Glassberg 2019). Nintedanib is an inhibitor of the various receptor such as receptor tyrosine kinases platelet derived growth factor, transforming growth factor-β receptor, vascular endothelial growth factor receptor and fibroblast growth factor. In vitro data have revealed that nintedanib interferes with the process of fibroblast proliferation, differentiation, migration and the secretion of extra cellular matrix component. Moreover, anti-inflammatory and anti-fibrotic action of nintedanib have been demonstrated in in vivo animal models of pulmonary fibrosis (Hu et al. 2014; Wollin et al. 2015). The antifibrosis effect of oral pirfenidone was investigated for its efficacy and tolerability in open label Phase II trial recruiting 54 patients at the last stage with advanced IPF. Patients were observed for the parameters of change in lung function and adverse effects. One and two-year survival was 78% and 63% respectively with pirfenidone therapy. Patients with impaired lung function before recruitment for this trial were stabilized after treatment. There were minor adverse effects associated with the treatment leading to the conclusion that pirfenidone is very well tolerated and could be a potential therapeutic option for IPF (Raghu et al. 1999).  The combination therapy of azathioprine (immunosuppressive medicine) plus prednisone (corticosteroid) and prednisone alone were compared for the therapeutic effect in 27 (14 and 13 respectively) newly diagnosed-previously untreated patient with IPF in a prospective, double-blind, randomized, placebo-controlled study. Azathioprine was well tolerated with few side effects. Changes in lung function at 1 yr, FVC, and single breath DLCO, were observed slightly better (but not statistically significant) in the azathioprine/prednisone combination as compared to prednisone alone. During a 9-year follow-up, death occurred in 6 out of 14 (43%) and 10 out of 13 (77%) patients in azathioprine/prednisone and prednisone alone respectively. Although not significant, but potentially advantage of survival with azathioprine/prednisone were observed by a Cox model survival analysis. Therefore, combining prednisone and azathioprine for treatment of IPF could be safe and possibly effective therapy. As exploratory placebo-controlled trail investigated the safety and efficacy of etanercept (a tumor necrosis factor inhibitor) 25 mg twice weekly in IPF recruiting 84 patients with clinically progressive IPF. The primary endpoints conducted were lung diffusing capacity for carbon monoxide corrected for hemoglobin (DlCOHb), % change of predicted FVC and change in the alveolar to arterial oxygen pressure difference P(a–a)O2 at rest from baseline over 48 weeks. Although etanercept was well tolerated as evident with no difference in adverse effect among treatment and placebo, there were also no significant differences in predefined efficacy endpoints. However, a decreased rate of disease progression was observed on several measures thus proposing further evaluation of TNF antagonists in the treatment of IPF (Raghu et al. 2008). Imatinib is an inhibitor of receptor tyrosine kinase having the potential to manage pulmonary fibrosis. A randomized placebo-controlled trial investigated the clinical effects and safety profile imatinib in 119 patients with IPF receiving wither imatinib or placebo for 96 weeks. However, imatinib did not show remarkable difference as compared to the placebo group in terms of time to disease progression or time to death. Moreover, there was no effect of imatinib therapy on change in forced vital capacity or change in DLCO at 48, 72, or 96 weeks. This trial concludes no benefit of imatinib 96 weeks therapy in terms of survival or lung function in patients with mild-moderate IPF (Daniels et al. 2010). Although a lot of clinical trials is ongoing to investigate the potential effective therapy for IPF, a larger randomized study is necessary to validate the results.
1.2.5.	Pleural effusion and cell signaling
Pleural effusion is characterised by neoplastic cells in the pleural fluid. It is the general clinical state in cancer individuals to have a neoplastic condition. Patients can sustain for around six months after the above-mentioned stage (Karkhanis and Joshi 2012). The prevailing conditions of pleural effusion include pain, cough and dyspnea (Berliner et al. 2016). Majorly lung and breast cancers are the driving forces behind pleural effusion. Apart from this gastrointestinal, lymphoma and genitourinary carcinoma also contributes to pleural effusion (Matthay et al. 1990). The extent of vascular endothelial growth factor in pleural fluid and serum intercellular adhesion molecule 1 are the possible factors for the persistence of individuals with lung adenocarcinoma and pleural effusion (Qian et al. 2012). The pleural effusion triggered by pulmonary malignancy may result in two directions (Psallidas et al. 2016). The first form is associated with effusion, which indirectly results from malignancy. In this bronchial carcinoma can block and destruct the lobe, leading to inflammatory effusion (Maia et al. 2018). The malignant individuals undergo pleural effusion lacking direct incorporation of pleural with the tumour (A. et al. 1996). The other form results in effusion directly governed by metastasis of serous membrane, inflammation of lymphocyte, mesothelium ulcer, fluid formation and capillary obstruction. Chronic inflammation is primarily seen in individuals with pleural effusion. The decreased expression of miR-198 acts as an indicator of lung adenocarcinoma with pleural effusion (Han et al. 2013). 
An unusual fluid around the lung is known as a pleural effect. The pleura is a thin layer covering the lung's surface and the chest wall's interior. When the pleural effusion happens, fluid builds up between the pleura membranes. In most instances, only teaspoons of watery fluid are in pleural space so that the lungs can pass easily through respiration in your chest cavity. Since Vascular endothelial growth factor (VEGF) has been shown to help form malignant pleural effusions, several attempts have been made to include it. The development of pleural effusion is multifunctional. Pleural effusion development is, at least, consistent with 1) decreased pleural space drainage due to blockage of arteries and lymphatics of the lung and pleura, ii) enhanced pleural shape, and iii) elevated systemic inflammation and subsequently increased permeability resulting in plasma leakage (Kinasewitz 1997).  PTK 787 is a phosphorylation inhibitor of a VEGF receptor tyrosine kinase. This agent's efficiency was tested in mice with malignant pleural effusion (Yano et al. 2000). Furthermore, Endostatin, a collagen XVIII 20kDa C-term fragment, is released from healthy tissues and cells. Endostatin potently inhibits angiogenesis and the growth of the tumor, demonstrating thoracoscopic talc infusion stimulates endostatious pleural mesothelial cells (Najmunnisa et al. 2007). Angiopoietin (Ang)-1 and -2 are key angiogenesis regulators that perform their actions by binding a joint tyrosine kinase (Tie-2) receptor, mainly on the surface of endothelial cells. Levels, but not Ang-1, are elevated in pleural exudations, which indicates that ang-2 and VEGF are part of pleural inflammation and the pathogenesis of pleural exudations (Tsigkos et al. 2003; Kalomenidis et al. 2006). No treatment may be required for small transudative effusions, while larger ones may be required for treatment. Drainage of pleural fluid is the primary therapy of choice. This is achieved by thoracentesis, where a chest tube is implanted in the effusion, and the result is pumped out (its technique may be therapeutic and diagnostic). Antibiotics are used when an inflammatory source occurs, whereas diuretics such as furosemide (Laasix) can gradually help in growing the degree of pleural effusion. The use of pleural effusion drugs is dependent on the underlying cause (Karkhanis and Joshi 2012; Carrington and Kruse 2019; Jany and Welte 2019)
1.2.6.	Pneumonia and cell signaling
Bacteria utilises the innate immune system of the lungs, which in turn leads to alteration in cell signaling mechanisms which eventually triggers the inflammatory cascade. As a consequence this sequence of events results in pneumonia (Martin and Frevert 2005). Bacteria associated with the epithelial cells of airways, then results in recruitment of chemokines to make phagocytes available at the site of infection (Li et al. 2012). TLR2 receptors present in the cells of the airways are capable of interacting with various types of pathogens. TLR2 in association with asialoGM1 gives the GalNAcGal receptor to P. aeruginosa pili, flagella and to various other pathogens (Feldman et al. 1998). The association of TLR2 and asialoGM1 are adjoined at the lipid layer which is then translocated to the site of infected airway cells. This thereby triggers the activator protein 1, CCAAT enhancer-binding protein, NF-kB, cAMP response element-binding protein which results in the liberation of granulocyte-macrophage colony-stimulating factor, MUC-2, and IL-6,8 (Adamo et al. 2004). 
The TNF-α receptor is also being triggered by the bacteria on airway epithelial cells, mainly by S. aureus protein A (Gómez et al. 2007). This protein A is extracted from the majority of individuals suffering from pneumonia. The bacteria on the surface of respiratory epithelial cells triggers the movement of TNFR1 (Parker and Prince 2012). The TNFR1-Protein A connection is vital for the infection of staphylococcal pneumonia. Activation of TNFR1 triggers the formation of IL-8,6 by the airway cells and also triggers TNF-α converting enzyme/ADAM-17 (Giai et al. 2013). TNF-α converting enzyme is a protease that aims for domains of (membrane proteins that are extended to extracellular space) various molecules like IL6R-α, TNF-α, and TNF-R1 (Horiuchi et al. 2010). TNF-α is a converting enzyme Moderate IL6R-α shedding, and its interaction with IL-6 and gp130 triggers trans-signaling (a process that inhibits expression of polymorphonuclear leukocyte chemokine and triggers macrophage chemokine, CCL2 generation) (Giai et al. 2013). These episodes lead to acute inflammatory reactions. (Kumar et al. 2017). Bacteria mediated TNF cascade has relevant anti-inflammatory effects that control the number of polymorphonuclear leukocytes. Thus epithelial cells of airways, without signals from immune cells, helps in engaging and monitoring of the polymorphonuclear leukocyte at the site of infection (Prince et al. 2006).
Inflammation and tissue consolidation due to an infectious agent is defined as pneumonia. Pneumonia is a severe and extreme form of acute low breathing infection. Inflammation and protective immunity are detected in the degrees of the lower respiratory infection results. Intercellular and interorgan signaling networks co-ordinate these infection control actions and tissue protection. A high mobility protein group box 1 (HMGB1), a ubiquitous nuclear protein, governs the composition of chromatin and modulates the function of a large number of lungs and other lung diseases implicated in the pathogenesis of lung cancer, including those controlling cell cycle regulation, cell death, and DNA replication and repair. Multiple pathways have been identified in association with severe pneumonia. For example, the susceptibility to severe infectious A / H1N1 pneumonia has been strongly associated with four single-nucleotide polymorphisms located in chromosomes 1 and 17 (Zúñiga et al. 2012). Moreover, early reports have shown that severe pneumonia with methicillin-resistant S is associated. S. aureus carrying chromosome mec sequence staphylococcal type IV and the leukocidin genes Panton leukocidin genes (Gillet et al. 2007). Besides, a recent study found that interleucine 10 (IL-10) and interferon protein (IP-10) were more explicitly associated with severe hypoxic Pneumonia in human immunodeficiency infants infected by the virus (Cordero-Coma et al. 2013). It has been reported that in some patients with severe pneumonia alone and moderate pneumonic disease patients with COPD, 645 and 528 differentially expressed genes (DEGs) were identified in a further analysis based on the results of the mRNA-seq test and bioinformatics. Among the DEGs, 88 genes were upregulated, and 80 genes were downregulated. The most widely downregulated genes in the co-expression network (e.g., ND1, ND3, ND4L, and ND6) and those typically upregulated (e.g., TSPY6P and CDY10P) were more heavily regulated. However, 131 genes with pneumonia associations have been predicted (including COX1, COX2, COX3, ND1, ND3, and ND6) (Feng et al. 2018). These three genes encode all cyclooxygenase encodes, which have a crucial part in various normal physiological functions, as well to regulate a range of pathological conditions, and also have the potential for pneumonia-relevant genes (COX1), COX2 and Cox3. 
In the co-expression network, many widely upregulated genes, including TSPY6P and CDY10P, often displayed a higher degree than those with downregulation (Poliseno et al. 2010). Besides, the research identified a pneumonia-based gene in 4 common upregulated genes (MIR449A, TAS2R43, MIR656, and EIF5AP4). MIR449A and MIR656, respectively, encoding miR-449a and miR-656. Moreover, it showed that miRNA-449a modulates the expression of the inflammative marker YKL40 through specific NOTCH pathway components. Besides, The primary pneumonia-related genes have been described as four widely upregulated genes (MIR449A, TAS2R43,MIR656, and EIF5AP4) . There is no sbelow - tandard treatment for pneumonia that's right for all. Most people depend on home remediation and herbal therapies for pneumonia treatments. The treatment is mainly relying on the management of the symptoms, controlling the fever with nonsteroidal anti-inflammatory medicine or acetaminophen (NSAIDs, like ibuprofen or naproxen) with plenty of fluids. Cipro, Levaquin, and Oracea have commonly prescribed antibiotics. Cough and cough suppressants help treat the symptoms of pneumonia. Analgesic pain relievers such as ibuprofen and acetaminophen are available for prescription. The prescription of antiviral and antifungal medication may be required for viral pneumonia or fungal pneumonia. Currently, Relenza (zanamivir) is a typical example of antivirus, and the prescription of fluconazole is usually antiphonic (Erdem et al. 2020; Igari et al. 2020).
A combined representation of the pharmacological strategies for chronic respiratory diseases has been depicted in figure 3 below:

Fig. 3. Pharmacological strategies with the potential to modify various cell signaling pathways in chronic respiratory disorders. These interventions primarily include inhibitors of specific biomolecules/receptors and/or immune factors that can differentially modulate immune pathways. 
2.	Conclusion & Future Prospects
Respiratory diseases represent a major public health problem with only limited therapeutic options. Despite advances in understanding the pathobiology of these groups of diseases, the treatment options are limited. In various molecular events, cell signaling pathways are the most important regulatory bodies for angiogenesis, apoptosis, metastasis, proliferation and cell resistance growth. Nevertheless, such mechanisms are still partly understood, rather than their role in the functioning of different cells. Combining cellular responses with appropriate visualization and quantitative analysis of the position of nano drugs will greatly facilitate the current understanding of the effects of the pharmacotherapeutic agents on the lungs and other organs. Future directions would be directed towards developing drugs that are more specific to modulate key signaling molecules that initiate and propagate the inflammatory responses by distinct mechanisms. The development of new, highly specific inhibitors with no major adverse effects are essential. With the rapid advancements in molecular biology and emerging strategies inefficiently disrupting protein-protein interaction, selective inhibitors could be developed in the near future which will play a big part and could serve as promising components.
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